Clinical trial
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for…
NCT00401011 · AEterna Zentaris, Industry · Completed
Key facts
| NCT number | NCT00401011 |
|---|---|
| Title | Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients |
| Official title | An Open-Label Phase I/II Study of the Safety and Efficacy of Perifosine and Bortezomib With or Without Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Bortezomib |
| Lead sponsor | AEterna Zentaris, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma, Multiple Myeloma in Relapse |
| Intervention type | Drug |
| Interventions | Perifosine, Bortezomib, Dexamethasone |
| Enrollment | 84 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Jul 1, 2011 |
| First posted | Nov 17, 2006 |
| Last update posted | Feb 23, 2018 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: